SCHEDULE: Eli Lilly Discloses 19.9% Stake in TRex Bio Post-IPO

Eli Lilly and Company has disclosed a beneficial ownership of 19.9% in TRex Bio, Inc. following its recent Initial Public Offering.

Summary

• Eli Lilly and Company (ELI) has filed a Schedule 13D, revealing its beneficial ownership of 5,480,872 shares of TRex Bio, Inc. (TRex Bio) common stock.
• This stake represents 19.9% of TRex Bio's outstanding shares as of October 13, 2026, following its IPO.
• The shares were acquired through conversions of Series A and Series B preferred stock and a direct purchase of 875,000 shares in the IPO for approximately $12.3 million.
• ELI acquired the IPO shares using cash on hand.
• The filing states the shares were acquired for investment purposes, with ongoing review of the investment.
• ELI may engage in discussions with TRex Bio's management, board, and other stockholders regarding operational, financial, and strategic initiatives.
• Julie Gilmore, an ELI employee, is a director on TRex Bio's board.
• ELI has entered into a 180-day lock-up agreement, restricting the sale or transfer of its shares until approximately April 5, 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, indicating a significant investment stake by a major pharmaceutical company post-IPO, with potential for strategic engagement.

Positives

• Significant investment by a major pharmaceutical company (Eli Lilly) in TRex Bio post-IPO.
• Eli Lilly's stake of 19.9% indicates strong confidence in TRex Bio's potential.
• The acquisition of shares through preferred stock conversion and IPO purchase demonstrates a strategic entry.
• The presence of an Eli Lilly representative on TRex Bio's board facilitates communication and potential collaboration.
• Customary registration rights are in place, providing potential future liquidity options for Eli Lilly.

Negatives

• The 180-day lock-up agreement restricts Eli Lilly's ability to sell or transfer its shares until approximately April 5, 2027.
• Eli Lilly does not have current agreements guaranteeing its ability to maintain its board seat or designate a replacement.

Risks

• Eli Lilly's investment strategy is subject to ongoing review, and future acquisitions or dispositions depend on various factors including market conditions and liquidity requirements.
• Potential for future strategic shifts by Eli Lilly regarding its investment in TRex Bio.
• The lock-up agreement limits immediate flexibility for Eli Lilly to divest its stake.

Future Outlook

Eli Lilly intends to continue reviewing its investment in TRex Bio on an ongoing basis and may engage in discussions regarding operational, financial, and strategic initiatives. The company may also acquire or dispose of additional securities of TRex Bio, subject to various factors.

Management Comments

• Eli Lilly and Company's principal business is the discovery, development, manufacturing, marketing and sale of pharmaceutical products worldwide.
• Eli Lilly acquired the shares for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.
• Eli Lilly may at any time and from time to time directly or indirectly acquire additional or all shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer, or dispose of any or all of its shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer.
• Eli Lilly expects to engage in discussions with directors, officers, members of management and representatives of TRex Bio, and may engage in discussions with stockholders, security holders or other interested parties, from time to time covering a range of topics concerning its investment and TRex Bio, including operational, financial and strategic initiatives.

Industry Context

StockSavvy.ai notes that this filing highlights a significant post-IPO investment by a major pharmaceutical player, Eli Lilly, into a biotechnology company, TRex Bio. This aligns with broader industry trends where large pharmaceutical companies actively seek to acquire or invest in innovative biotech firms to bolster their pipelines and access new technologies.

Related Party Transactions

• Julie Gilmore, an employee of Eli Lilly and Company, is a member of TRex Bio's board of directors.

Stakeholder Impact

• Shareholders of TRex Bio may benefit from the validation and potential strategic support provided by Eli Lilly's significant investment.
• Potential for increased collaboration and resource allocation for TRex Bio due to Eli Lilly's involvement.
• Creditors and suppliers may view TRex Bio more favorably due to the backing of a large, stable pharmaceutical company.

Next Steps

• Eli Lilly will continue to review its investment in TRex Bio.
• Eli Lilly may engage in discussions with TRex Bio's management, board, and other stakeholders.
• Eli Lilly may acquire or dispose of additional securities of TRex Bio.
• Eli Lilly may engage in hedging or other derivative transactions with respect to TRex Bio securities.
• Eli Lilly may retain consultants and advisors and enter into discussions with potential sources of capital and other third parties.

Key Dates

Recommendation

The filing indicates a significant investment by a major player, which is positive. However, the investment is for 'investment purposes' with ongoing review, and the lock-up period restricts immediate action. While strategic engagement is possible, there are no immediate catalysts for a strong buy or sell, making 'hold' appropriate pending further developments.

Keywords

TRex Bio, Eli Lilly, Schedule 13D, Investment, IPO, Beneficial Ownership, Pharmaceutical, Biotechnology